CGCN GROUP, LLC

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Biopharmaceutical Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $80,000.00 income · posted Apr 20, 2026

Bills named in this filing 2

Lobbying activity 2

Health Issues

Access to innovative non-opioid medicines.

Medicare/Medicaid

Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.